DB:QA9

Stock Analysis Report

Executive Summary

Alchemia Limited does not have significant operations.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Alchemia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QA9 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

QA9

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

0%

QA9

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: QA9 underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: QA9 underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

QA9IndustryMarket
7 Day0%11.7%9.9%
30 Day0%-5.9%-16.6%
90 Day0%-22.6%-24.8%
1 Year0%0%-7.9%-8.1%-15.0%-17.5%
3 Year0%0%16.6%15.4%-17.4%-24.5%
5 Year-99.7%-99.7%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Alchemia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Alchemia undervalued compared to its fair value and its price relative to the market?

2.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QA9's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QA9's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QA9 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: QA9 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QA9's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QA9 is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Alchemia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

57.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alchemia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Alchemia performed over the past 5 years?

27.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QA9 is currently unprofitable.

Growing Profit Margin: QA9 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QA9 is unprofitable, but has reduced losses over the past 5 years at a rate of 27.1% per year.

Accelerating Growth: Unable to compare QA9's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QA9 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: QA9 has a negative Return on Equity (-21.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is Alchemia's financial position?


Financial Position Analysis

Short Term Liabilities: QA9's short term assets (A$1.6M) exceed its short term liabilities (A$53.2K).

Long Term Liabilities: QA9 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: QA9 is debt free.

Reducing Debt: QA9 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: QA9 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if QA9's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QA9 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: QA9 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 39.2% each year


Next Steps

Dividend

What is Alchemia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QA9's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QA9's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QA9's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QA9's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QA9's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average board tenure


CEO

Alchemia has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Melanie Leydin
CFO, Company Secretary & Director0.25yrAU$84.00kno data
Terence Brown
Member of Clinical Advisory Boardno dataAU$257.68kno data
Leonard Saltz
Member of Clinical Advisory Boardno datano datano data
Eric Cutsem
Member of Clinical Advisory Boardno datano datano data
Cameron Petricevic
Chairman0.25yrAU$2.08kno data
Peter Gibbs
Chairman of Clinical Advisory Boardno datano datano data
Ian Chau
Member of Clinical Advisory Boardno datano datano data
Lynden Polonsky
Director0.25yrno datano data

0.3yrs

Average Tenure

Experienced Board: QA9's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Alchemia Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alchemia Limited
  • Ticker: QA9
  • Exchange: DB
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$3.572m
  • Listing Market Cap: AU$2.187m
  • Shares outstanding: 324.72m
  • Website: https://www.alchemia.net.au

Number of Employees


Location

  • Alchemia Limited
  • 100 Albert Road
  • Level 4
  • South Melbourne
  • Victoria
  • 3205
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACLASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2003
QA9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2003
ACLCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2003
AEMA.FOTCPK (Pink Sheets LLC)SHSUSUSDMar 2004

Biography

Alchemia Limited does not have significant operations. Previously, it was engaged in developing oncology products. The company seeks out business development opportunities in the life sciences and other sectors. Alchemia Limited was founded in 1995 and is based in South Melbourne, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/26 03:00
End of Day Share Price2019/03/28 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.